Corcept Therapeutics Incorporated CORT
Set alert
81.12 USD -4.83 -5.62%
At close · Oct 30
81.12 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
80.28 Day range 85.31
32.15 52-week range 123.57
- YTD
- +133.10%
- 1 year
- +12.26%
- Open
- 84.87
- Prev close
- 85.95
- Mkt cap
- 8.77B
- Vol
- 1.43M
- Avg vol
- 1.18M
- EPS
- 0.45
- P/E
- 180.27
- Div yield
- 0.00%
More statistics
- Low
- 80.28
- High
- 85.31
- Forward P/E
- 19.33
- Beta
- 0.40
- Short ratio
- 5.51
- Inst. own
- 77.19%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 112.78
- 200-d avg
- 74.55
- 1y target
- 141.00
6M chart
Events in this range
- Jul 27, 2026Downgrade: Wolfe Research · Peer Perform → Underperform
- Jul 29, 2026Earnings: 0.36; estimate 0.02427; surprise 1383.31%
- Jul 29, 2026Rating: Canaccord Genuity · Buy → Buy
- Jul 30, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Jul 30, 2026Rating: Canaccord Genuity · Buy → Buy
- Jul 30, 2026Rating: Piper Sandler · Overweight → Overweight
- Sep 18, 2026Rating: HC Wainwright & Co. · Buy → Buy
Signals (21)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 15, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 5, 2026 | 3 weeks ago |
| MACD: Sell Signal | Aug 26, 2026 | 2 months ago |
| RSI: Overbought | Aug 20, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 17, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 13, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 30, 2026 | 3 months ago |
| RSI: Overbought | Jul 30, 2026 | 3 months ago |
| RSI: Overbought | Jul 21, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 7, 2026 | 3 months ago |
| MACD: Sell Signal | Jun 22, 2026 | 4 months ago |
| RSI: Overbought | May 19, 2026 | 5 months ago |
| RSI: Overbought | May 13, 2026 | 5 months ago |
| SMA: Bullish | May 1, 2026 | 6 months ago |
| RSI: Overbought | May 1, 2026 | 6 months ago |
Key statistics
- Market cap
- 8.77B
- Enterprise value
- 8.99B
- Trailing P/E
- 180.27
- Forward P/E
- 19.33
- PEG ratio
- 0.81
- Price / sales
- 10.55
- Price / book
- 12.40
- EPS (TTM)
- 0.45
- Beta
- 0.40
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 6.64%
- Revenue (TTM)
- 830.81M
- Revenue growth
- 31.70%
- Free cash flow
- 77.40M
- Total cash
- 308.20M
- Total debt
- 9.42M
- Return on equity
- 8.23%
- Shares outstanding
- 108.10M
- Short % of float
- 10.24%
- 50-day average
- 112.78
- 200-day average
- 74.55
Analyst view
Consensus: buy
Buy
Price target (mean) 141.00 +73.8% upside
Now 81.12
- Target (low)
- 50.00
- Target (mean)
- 141.00
- Target (high)
- 165.00
Ratings (0m) 5 4 buy · 0 hold · 1 sell
- Strong buy1
- Buy3
- Hold0
- Sell1
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate 0.84.
Financials — quick view
CORT Revenue — quarterly 256.15M
CORT Net income — quarterly 42.14M
CORT EPS — quarterly 0.40
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | 0.794 | — | — | — |
| Jul 29, 2026 | Jun 30, 2026 | 0.02427 | 0.36 | +0.34 | +1,383.31% |
| Apr 30, 2026 | Mar 31, 2026 | -0.11019 | -0.30 | -0.19 | -172.26% |
| Feb 24, 2026 | Dec 31, 2025 | 0.33 | 0.20 | -0.13 | -39.39% |
| Nov 4, 2025 | Sep 30, 2025 | 0.18 | 0.16 | -0.02 | -11.11% |
| Jul 31, 2025 | Jun 30, 2025 | 0.23 | 0.29 | +0.06 | +26.09% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 30, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Jul 30, 2026 | Canaccord Genuity | main | Buy | Buy |
| Jul 30, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 29, 2026 | Canaccord Genuity | main | Buy | Buy |
| Jul 27, 2026 | Wolfe Research | down | Peer Perform | Underperform |
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- corcept.com
News
- Corcept Reports Favorable Survival and Response Data in Ovarian Cancer Study
- Corcept Therapeutics Announces Results From Part A Of Its Phase 2 BELLA Trial Of Lifyorli In Combination With Nab-Paclitaxel And Bevacizumab In Patients With Ovarian Cancer; Lifyorli In Combination With Nab-Paclitaxel And Bevacizumab Demonstrated Clinically Meaningful Progression-Free Survival, Objective Response Rate And Overall Survival
- Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
- Oil Tops $100 on Iran Fears, Energy ETF XLE Hits New Record: Stock Market Today
- 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
- 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
- Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?
- Corcept Therapeutics (NASDAQ:CORT) Director Sells $1,148,100.00 in Stock
- Corcept Therapeutics Incorporated $CORT Stock Holdings Cut by First Citizens Bank & Trust Co.
- Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains
Your note
Sign in to keep a note on CORT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER GEORGE LEONARD JR. | Director | Purchase | Mar 16, 2026 | 5,550,200 |
| BELANOFF JOSEPH K | Chief Executive Officer | Sale | May 31, 2026 | 0 |
| GUYER WILLIAM | Officer | Stock Award(Grant) | Aug 31, 2026 | 4,313 |
| HUNT HAZEL | Officer | Conversion of Exercise of derivative security | Feb 8, 2026 | 255,437 |
| LYON JOSEPH DOUGLAS | Chief Technology Officer | Conversion of Exercise of derivative security | Oct 1, 2026 | 5,683 |
| MADUCK SEAN | Officer | Conversion of Exercise of derivative security | Oct 1, 2026 | 119,655 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 11.50% | 12,432,023 | 1.01B | Jun 29, 2026 |
| Ingalls & Snyder LLC | 7.34% | 7,934,507 | 643.65M | Jun 29, 2026 |
| Renaissance Technologies, LLC | 4.87% | 5,261,628 | 426.82M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.67% | 5,044,638 | 409.22M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.86% | 4,172,482 | 338.47M | Jun 29, 2026 |
| Parallel Advisors, LLC | 3.67% | 3,962,177 | 321.41M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.13% | 3,388,420 | 274.87M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.68% | 2,893,842 | 234.75M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.94% | 2,093,441 | 169.82M | Jun 29, 2026 |
| Fidelity Contrafund | 1.35% | 1,464,100 | 118.77M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.12% | 1,205,900 | 97.82M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.01% | 1,095,943 | 88.90M | Jun 29, 2026 |